Education
About Us
Working with TipRanks
Follow Us
Altimmune (ALT)
:ALT
Total Valuation
Altimmune has a market cap or net worth of $452.58M. The enterprise value is ―.
Market Cap$452.58M
Enterprise Value―
Share Statistics
Altimmune has 81,106,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,106,970
Owned by Insiders0.86%
Owned by Institutions10.69%
Financial Efficiency
Altimmune’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -79.91%.
Return on Equity (ROE)-0.77
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-79.91%
Return on Capital Employed (ROCE)-0.80
Revenue Per Employee338.98
Profits Per Employee-1.61M
Employee Count59
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Altimmune is -5.39. Altimmune’s PEG ratio is -0.29.
PE Ratio-5.39
PS Ratio0.00
PB Ratio3.07
Price to Fair Value4.14
Price to FCF-5.13
Price to Operating Cash Flow-4.75
PEG Ratio-0.29
Income Statement
In the last 12 months, Altimmune had revenue of 20.00K and earned -95.06M in profits. Earnings per share was -1.34.
Revenue20.00K
Gross Profit20.00K
Operating Income-103.17M
Pretax Income-95.06M
Net Income-95.06M
EBITDA-94.81M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -79.85M and capital expenditures 0.00, giving a free cash flow of -79.85M billion.
Operating Cash Flow-79.85M
Free Cash Flow-79.85M
Free Cash Flow per Share-0.98
Dividends & Yields
Altimmune pays an annual dividend of $873, resulting in a dividend yield of ―
Dividend Per Share$873
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.27
52-Week Price Change-30.34%
50-Day Moving Average5.19
200-Day Moving Average6.60
Relative Strength Index (RSI)53.84
Average Volume (3m)2.34M
Important Dates
Altimmune upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend DateFeb 06, 2017
Financial Position
Altimmune as a current ratio of 13.11, with Debt / Equity ratio of 1.36%
Current Ratio13.11
Quick Ratio13.11
Debt to Market Cap0.00
Net Debt to EBITDA0.37
Interest Coverage Ratio-11.46K
Taxes
In the past 12 months, Altimmune has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Altimmune EV to EBITDA ratio is -5.03, with an EV/FCF ratio of -5.97.
EV to Sales23.83K
EV to EBITDA-5.03
EV to Free Cash Flow-5.97
EV to Operating Cash Flow-5.97
Balance Sheet
Altimmune has $131.89M in cash and marketable securities with $1.68M in debt, giving a net cash position of -$130.21M billion.
Cash & Marketable Securities$131.89M
Total Debt$1.68M
Net Cash-$130.21M
Net Cash Per Share-$1.61
Tangible Book Value Per Share$1.74
Margins
Gross margin is -740.00%, with operating margin of -515860.00%, and net profit margin of -475295.00%.
Gross Margin-740.00%
Operating Margin-515860.00%
Pretax Margin-475295.00%
Net Profit Margin-475295.00%
EBITDA Margin-474060.00%
EBIT Margin-475250.00%
Analyst Forecast
The average price target for Altimmune is $21.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.86
Price Target Upside291.76% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-95.12%
EPS Growth Forecast21.09%